Back to Search
Start Over
Use of JAK inhibitors in the management of myelofibrosis: a revision of the British Committee for Standards in Haematology Guidelines for Investigation and Management of Myelofibrosis 2012.
Use of JAK inhibitors in the management of myelofibrosis: a revision of the British Committee for Standards in Haematology Guidelines for Investigation and Management of Myelofibrosis 2012.
- Source :
-
British journal of haematology [Br J Haematol] 2014 Nov; Vol. 167 (3), pp. 418-20. Date of Electronic Publication: 2014 Jun 25. - Publication Year :
- 2014
- Subjects :
- Anemia chemically induced
Humans
Maximum Tolerated Dose
Nitriles
Primary Myelofibrosis complications
Primary Myelofibrosis enzymology
Protein Kinase Inhibitors administration & dosage
Protein Kinase Inhibitors adverse effects
Pyrazoles adverse effects
Pyrimidines
Recurrence
Splenomegaly drug therapy
Splenomegaly etiology
Symptom Assessment
Thrombocytopenia chemically induced
Janus Kinase 1 antagonists & inhibitors
Janus Kinase 2 antagonists & inhibitors
Primary Myelofibrosis drug therapy
Protein Kinase Inhibitors therapeutic use
Pyrazoles therapeutic use
Subjects
Details
- Language :
- English
- ISSN :
- 1365-2141
- Volume :
- 167
- Issue :
- 3
- Database :
- MEDLINE
- Journal :
- British journal of haematology
- Publication Type :
- Editorial & Opinion
- Accession number :
- 24961987
- Full Text :
- https://doi.org/10.1111/bjh.12985